PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon
PITUICARE-Lyon
PITUItary Carcinomas or Aggressive Tumors REgistry: Monocentric Study Form a Cohort of Patient Operated on for Pituitary Tumors in University Hospital of Lyon (France)
1 other identifier
observational
1,300
1 country
1
Brief Summary
The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome information on patients harboring pituitary mass lesions of all types.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2007
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2015
CompletedFirst Submitted
Initial submission to the registry
July 27, 2016
CompletedFirst Posted
Study publicly available on registry
August 3, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedAugust 3, 2016
July 1, 2016
8.8 years
July 27, 2016
July 29, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Progression free survival after pituitary surgery according to the clinicopathological classification (HYPOPRONOS)
Clinical, biochemical et imaging evaluation of a cohort of patient operated in the referral center for pituitary tumor. Identification of recurrence or progression an analysis of the clinicopathological classification. Evaluation of the different therapeutic strategies (med, surgery, chemotherapies, radiation therapy) to prevent recurrence or tumor progression.
up to 10 years (postoperatively)
Secondary Outcomes (2)
Correlation between percentage of SSTR expression of the pituitary tumor and somatostatine analogs efficacy.
2007-2020
Correlation between percentage of MGMT expression of the pituitary tumor and tumor response to temozolomide.
2007-2020
Eligibility Criteria
tertiary referral center
You may qualify if:
- patients with confirmed pituitary disease
You may not qualify if:
- patients who do not have confirmed pituitary disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Groupement Hospitalier Est, Lyon, France
Bron, 69500, France
Related Publications (1)
Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, Jouanneau E, Roy P, Trouillas J. Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3368-3374. doi: 10.1210/jc.2017-00773.
PMID: 28651368DERIVED
Biospecimen
DNA and pituitary tumor frozen sample (Neurobiotec Biological Resource Centre (BRC) of Hospices Civils de Lyon (HCL))
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Gerald Raverot, MD PhD
Hospices Civils de Lyon
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 27, 2016
First Posted
August 3, 2016
Study Start
February 1, 2007
Primary Completion
December 1, 2015
Study Completion
December 1, 2020
Last Updated
August 3, 2016
Record last verified: 2016-07